PLUS THERAPEUTICS

Plus Therapeutics is dedicated to developing and delivering innovative cell-based therapies to improve the quality and length of life. It is a global, public company engaged in the development and commercialization of stem and regenerative cell therapies for the treatment of cardiovascular disease, reconstructive surgery, and other serious, chronic, and life-threatening conditions. Plus Therapeutics pipeline of candidate drug products includes their lead drug product candidates, RNL and DocePLUS, which are being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians, and other professionals.